
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera Inc is positioned for positive revenue growth, driven by increased demand for its Signatera product, which saw a significant sequential rise in clinical units, outpacing expectations. The company's gross margin guidance has been raised, suggesting healthy operational efficiency and a favorable outlook on average selling prices, bolstered by expectations of expanded reimbursement coverage in oncology. Additionally, the strong growth in new Signatera patient additions, alongside the promising clinical outcomes demonstrated in partnership with Genentech, underscores a robust market acceptance and potential for sustained financial performance.
Bears say
Natera faces significant financial challenges, primarily due to anticipated margin erosion resulting from in-network pricing reductions as more commercial payors join the market, which could broaden the total addressable market but diminish profitability. The company's ongoing cash burn and historic lack of profitability raise concerns about its financial viability, particularly if reimbursement for its tests is reduced or if it fails to secure adequate reimbursement rates. Additionally, competition from superior diagnostic tests and potential regulatory changes pose further risks that could adversely impact Natera's market position and financial performance.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares